Stem Cells Translational Medicine · 2 authors, 3 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This 3-year prospective study compared the effects of subtenon Wharton's jelly-derived mesenchymal stem cells (WJ-MSC), Magnovision electromagnetic stimulation, their combination, and no treatment on the progression of retinitis pigmentosa. The combination therapy resulted in the least disease progression across multiple anatomical and functional measures.
This prospective, sequential, open-label clinical study evaluated 130 eyes from 80 retinitis pigmentosa patients across four groups: WJ-MSC alone, Magnovision alone, combined WJ-MSC and Magnovision, and an untreated control. Over 36 months, anatomical and functional retinal changes were measured. The combination therapy (Group 3) showed the smallest decline in FAF-field (0.07 mm²) and the best preservation of EZW, BCVA, and FPDI. The control group (Group 4) exhibited the most severe progression (e.g., FAF-field change of 12.04 mm²). The WJ-MSC alone and Magnovision alone groups showed intermediate results. The study suggests the combination significantly slows disease progression compared to the natural course. Limitations include the open-label design, sequential group allocation, and the absence of a true placebo for the control group.
